Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Crossref
1. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir
- Fa- Da Wang
- Jing Zhou
- Lan-Qing Li
- Yu-Jing Li
- Meng-Lan Wang
- Ya-Chao Tao
- Dong-Mei Zhang
- Yong-Hong Wang
- En-Qiang Chen
2. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
- Zhi-Hao Zeng
- Jin-Qing Liu
- Min Zhang
- Cai-Liang Qiu
- Zhen-Yu Xu
4. Comparative Efficacy and Renal Safety of Entecavir and Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B: A Retrospective Cohort Study From Vietnam
- Thong Duy Vo
- Han Ngoc Gia Nguyen
- Sang The Phan
5. Metabolic effects and cardiovascular disease risks of TDF or TAF in patients with chronic hepatitis B: a systematic review and meta-analysis
- Yuan-Hai Zhou
- Nan Cai
- Yu-Xin Chen
- Yong-Lu Su
- Peng Hu
7. Impact of Tenofovir Alafenamide on Lipid Profiles in Chronic Hepatitis B Patients: Systematic Review and Meta‐Analysis
- Ping‐Yu Hsu
- Hui‐Chen Su
- Mi‐Chia Ma
- Chien‐An Chen
- Sin‐Yi Yu
- Yi‐Ming Hua
8. The Effects of the COVID-19 Pandemic on Clinical and Laboratory Follow-up of Patients Diagnosed With Chronic Hepatitis B: A Multicenter, Prospective, Observational Study
- Fethiye Akgul
- Yusuf Arslan
- Mehmet Celik
- Omer Karasahin
- Mustafa Kemal Celen
9. Effects of first-line nucleot(s)ide analogues on lipid profiles in patients with chronic hepatitis B: a network meta-analysis
- Kexin Tong
- Mingjing Chen
- Danni Wang
- Haifeng Dai
- Jiayi Peng
- Jia Zhang
- Jiao Zhou
- Yujiao Chang
- Wenxiang Huang